Gene: ZNF503

84858
NOLZ-1|NOLZ1|Nlz2
zinc finger protein 503
protein-coding
10q22.2
Ensembl:ENSG00000165655 MIM:613902 Vega:OTTHUMG00000018526 UniprotKB:Q96F45
NC_000010.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.734e-2 (AD)  7.426e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12267051chr10:75346879 (GRCh38.p7)C>G / C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZDHHC180.739
CCDC860.713
IFNGR20.711
EIF1AD0.701
SNAPC20.696
NOB10.693
SF3B40.69
MED260.688
PINX10.684
RAI20.683

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.469
OR4F29-0.449
C16orf96-0.299
ALDH1L1-AS2-0.283
PDE11A-0.276
CRB1-0.269
GLI1-0.264
ZNF98-0.26
ASB4-0.253
PON1-0.251

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of ZNF503 mRNA22100608
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of ZNF503 mRNA21298039
D001280AtrazineAtrazine results in increased expression of ZNF503 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ZNF503 mRNA21839799
D004958EstradiolEstradiol affects the expression of ZNF503 mRNA22574217
C044887beta-methylcholinebeta-methylcholine affects the expression of ZNF503 mRNA21179406
C006780bisphenol Abisphenol A results in increased expression of ZNF503 mRNA26364221
C006780bisphenol Abisphenol A affects the expression of ZNF503 mRNA21786754
C006780bisphenol Abisphenol A results in increased expression of ZNF503 mRNA25181051
C584509C646 compoundC646 compound results in decreased expression of ZNF503 mRNA26191083
D002104CadmiumCadmium results in decreased expression of ZNF503 mRNA24067728
C029892cupric chloridecupric chloride results in decreased expression of ZNF503 mRNA21072851
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of ZNF503 mRNA23914054
D003907DexamethasoneDexamethasone results in decreased expression of ZNF503 mRNA25047013
D002945CisplatinCisplatin results in decreased expression of ZNF503 mRNA27392435
D002945CisplatinCisplatin results in increased expression of ZNF503 mRNA19561079|2759478
C118739entinostatentinostat results in decreased expression of ZNF503 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
D004397FonofosFonofos results in increased methylation of ZNF503 promoter22847954
D019833GenisteinGenistein results in increased expression of ZNF503 mRNA26865667
C045463leflunomideleflunomide results in increased expression of ZNF503 mRNA28988120
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of ZNF503 mRNA26011545
D009532NickelNickel results in decreased expression of ZNF503 mRNA25583101
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of ZNF503 mRNA25729387
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of ZNF503 mRNA26272509
D010278ParathionParathion results in increased methylation of ZNF503 promoter22847954
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of ZNF503 mRNA26272509
D012834SilverSilver results in decreased expression of ZNF503 mRNA26014281
C012568terbufosterbufos results in increased methylation of ZNF503 promoter22847954
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of ZNF503 mRNA28065790
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of ZNF503 mRNA25729387
D019772TopotecanTopotecan results in increased expression of ZNF503 mRNA25729387
D014212TretinoinTretinoin results in decreased expression of ZNF503 mRNA23724009
D014212TretinoinTretinoin results in increased expression of ZNF503 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of ZNF503 mRNA24935251|2627250
C057693troglitazonetroglitazone results in decreased expression of ZNF503 mRNA28973697
D014520UrethaneUrethane results in increased expression of ZNF503 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of ZNF503 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased expression of ZNF503 mRNA23179753|2718838
D014635Valproic AcidValproic Acid results in increased methylation of ZNF503 gene29154799
C034028vanadyl sulfatevanadyl sulfate results in decreased expression of ZNF503 mRNA16330358
D014750VincristineVincristine results in decreased expression of ZNF503 mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003676nucleic acid binding-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006351transcription, DNA-templated-IEA-  
GO:0006355regulation of transcription, DNA-templated-IEA-  
GO:0008285negative regulation of cell proliferation-IDA20735826  
GO:0010629negative regulation of gene expression-IDA20735826  
GO:0061351neural precursor cell proliferation-IEA-  
GO:0070315G1 to G0 transition involved in cell differentiation-IDA20735826  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal